Didn't the company say in a presentation their cost per patient for the trial was low? I seem to recall $10K or something like that and much of the cost was picked up by somewhere else. I think it may have been a question after a presentation but don't remember where/when. Sure someone here does.
(2)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links